Presentation at CRT Meeting in Washington

Prof. Mohl, founder of AVVie, recently presented at the 2020 CRT Conference in Washington.
CRT, one of the world’s leading interventional cardiology conferences organized by Cardiovascular Research Technologies (CRT) Group Foundation, took place on February 22 – 25 2020. On February 24th, Prof. Mohl gave his presentation entitled „Percutaneous mitral valve repair with artificial papillary muscle“.

On the same day, AVVie’s chairman was interviewed for Cardiotube. To watch the whole discussion, please visit: httpss://

AVVie GmbH (‘Angel Valve’) achieved important milestone

Mitral Butterfly is a proprietary chordal repair technique restoring the coaptation plane of a flail leaflet in degenerative mitral regurgitation. Additionally, the unique deployment technique restores the support apparatus of the mitral valve in one step. It is an unparalleled technique and a differentiated method from presently known repair concepts. The primary advantage of the mechanism of action containing the prolapsing segment is the introduction of an artificial papillary muscle as valvular support.

The Mitral Butterfly device is intended to advance chordal repair. The present chronic animal study was to demonstrate safety of the device at 90-day follow-up. There were no device related adverse effects and no deterioration of valve function during follow up. All safety endpoints were met, and structural integrity was maintained out to an average of 12 million cycles per animal.

Patrick Maguire MD, MBA, said: “the successful completion of the chronic animal study is a major step in the development of a feasible mitral repair system and an advancement of mitral innovation”. Werner Mohl, MD, PhD, Founder of AVVie added: “we are pleased to reach this important milestone in line with our ambitious development plan. We are committed to bring a safe and effective device to the clinical arena.

AVVie wins BoB Award 2019

AVVie GmbH has been announced as the start-up track winner in the category MedTech in the Best of Biotech (BoB) 2019 Ceremony Awards.
BoB – Best of Biotech is an international life science businessplan competition recognizing life science innovations and honoring scientists. The BoB award program gives innovators a chance to stand out in the life science community and motivates them to become entrepreneurs. The aim of BoB is to promote Austria and Central Europe as a life science business incubator, active in the pharmaceutical, biotech and medtech fields.

On 23rd of October 2019 the Austrian Federal Ministry for Digital and Economic Affairs and Austria Wirtschaftsservice announced the award winners at the aws Bob – Best of Biotech: Award Ceremony (httpss://, the prestigious gathering of the best early phase pitches and the best start up projects in each of the following categories: biotech/pharma, medtech and digital health. Finalists were selected by a group of experienced judges and, from the group of finalists, one winner from each category was awarded.

AVVie wins S&B (Science and Business)

This year AVVie has been chosen to be among the 10 best start-ups and had the opportunity to take part in the S&B Award competition. The S&B (Science and Business)-Award granted by Rudolf Sallinger Fonds awards scientific entrepreneurs.

The Mitral Butterfly competed with other 9 great projects and each one of them was a strong competitor. AVVie representatives, together with Prof. Mohl presented the innovative idea in front of a professional jury and awaited the verdict.

At the gala on 19th of June, AVVie was announced to be a winner of S&B Award 2019. AVVie won the competition and was awarded with a 20.000 € price.

Mitral Butterfly at the TVT Structural Heart Summit

“Mitral Butterfly” will be presented in one of the most prestigious meetings for structural heart innovations worldwide.

Moreover, the abstract „Mitral Butterfly: Evaluation of a novel device in porcine and human hearts“ has been accepted and will be presented at the TVT Moderated Poster Session.
It is a great scientific success and a unique opportunity to be a part of such a clinically-relevant conference in structural heart disease.

It is an honour to be actively involved in the innovation session of the TVT Structural Heart Summit in Chicago this year.

AVVie wins Austrian Founder Award Phoenix

AVVie GmbH won the Austrian Founder Award Phoenix 2018 in the category “Prototype”. This award validates prototype projects in basic research and development co-financed through public grants by the Austrian Research Promotion Agency (Österreichische Forschungsförderungsgesellschaft mbH, FFG) and the Austria Wirtschaftsservice Gesellschaft mbH (aws).

A distinguished jury selected AVVie as a Phoenix laureate and the award was presented jointly by the Austrian Minister of Digital and Economic Affairs and the Austrian Minister of Education, Science and Research during a prize ceremony on December 3rd 2018 in Vienna.

Mitral Butterfly shortlisted at EACTS

Mitral Butterfly shortlisted at EACTS Techno-College Innovation Award.

An abstract on AVVie’s technology has been shortlisted as one of five finalists at the EACTS Techno-College Innovation Award. Professor Werner Mohl presented the Mitral Butterfly implant in front of a judging panel and assembled audience in a rapid response format on October 20thas part of the Lion’s Den session in Milano.

An Update is presented at the PCR London Valves 2018

An Update of the Mitral Butterfly technology is presented at the PCR London Valves 2018

In June of 2018, Prof. Werner Mohl MD, PhD, was asked to present an update on the Angel Valve Mitral Butterfly implant at the prestigious PCR London Valves 2018 Innovator’s Day on September 9th.  The presentation is included in the „Emerging Mitral Devices“ section of the program.

PCR London Valves Innovator’s Day 2017

Johanna Ticar presented the results of Mitral Butterfly®´s first in vitro tests at 2017 PCR London Valves Innovator´s Day. The three day international conference brought over 2000 interventional cardiologists as well as representatives of the cardiovascular device industry together to discuss the latest trends in the field.